v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc stockholders
Ordinary Shares
Additional Paid-in-Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Deferred A Shares
Deferred Shares
Beginning balance (in shares) at Dec. 31, 2023     38,643,540         63,443
Beginning balance at Dec. 31, 2023 $ 186,995 $ 186,784 $ 1 $ 386,602 $ (176,590) $ (23,315) $ 211 $ 86
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 1,615 1,615   1,615        
Issue of ordinary shares, net of issuance costs (in shares)     309,416          
Issue of ordinary shares, net of issuance costs 503 503 $ 0 [1] 503        
Foreign currency translation adjustments (1,577) (1,580)       (1,580) 3  
Net loss (15,520) (15,489)     (15,489)   (31)  
Ending balance (in shares) at Mar. 31, 2024     38,952,956         63,443
Ending balance at Mar. 31, 2024 172,016 171,833 $ 1 388,720 (192,079) (24,895) 183 $ 86
Beginning balance (in shares) at Dec. 31, 2024     40,234,663         63,443
Beginning balance at Dec. 31, 2024 130,135 130,029 $ 1 393,474 (237,664) (25,868) 106 $ 86
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 468 468   468        
Issue of ordinary shares, net of issuance costs (in shares)     104,732          
Issue of ordinary shares, net of issuance costs 2 2 $ 0 [1] 2        
Foreign currency translation adjustments 4,646 4,643       4,643 3  
Net loss (19,658) (19,648)     (19,648)   (10)  
Ending balance (in shares) at Mar. 31, 2025     40,339,395         63,443
Ending balance at Mar. 31, 2025 $ 115,593 $ 115,494 $ 1 $ 393,944 $ (257,312) $ (21,225) $ 99 $ 86
[1] Indicates amount less than one thousand